FDA Brief

Warning letters Devices

FDA warning letter to

3B Medical, Inc. dba Reach Health, Inc.

High riskIssued May 20Posted Jun 30Center for Devices and Radiological Health

FDA warns Reach Health over unapproved APAP use change and complaint/CAPA failures.

What happened

FDA inspected 3B Medical/Reach Health in Dublin, OH from December 1, 2025 through December 10, 2025. FDA found complaint handling, CAPA, design risk, training, and unapproved-device violations. FDA also reviewed the firm's website manuals and found Luna APAP devices labeled for multi-patient hospital reuse without clearance, and found missing MDR follow-up for choking and shortness-of-breath complaints.

What FDA found

  1. The firm cancelled or logged as inquiries many customer contacts that met its own complaint definition, including pressure, shutdown, software, oxygen-concentrator, and mask-durability allegations.

    21 CFR 820.198(a)
  2. For complaints alleging choking or shortness of breath, the firm did not ask follow-up questions needed to decide whether the events were reportable to FDA, and no MDR was filed.

    21 CFR 820.198(a)(3)
  3. Complaint processing was not timely; the firm had large backlogs of open complaints and too few staff, including temporary staff, handling them.

    21 CFR 820.198(a)(1)
  4. The firm's CAPA process failed to cover all warehouses for expired cannulae and did not link the field action, and its complaint trend review did not trigger CAPAs by model.

    21 CFR 820.100(a), (a)(1)
  5. The firm accepted an outdated 2016 risk report for iCodeConnect and did not assess risk acceptability of later software and ventilator-compatibility changes.

    21 CFR 820.30(g)
  6. The firm distributed Luna G3 APAP and G3X APAP devices with labeling for multi-patient hospital reuse without the required clearance or approval for that major intended-use change.

    21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 352(o); 21 CFR 807.81(a)(3)

What FDA wants

FDA asks the firm to respond with a plan to fix each cited deficiency and to keep providing updates and supporting evidence for its corrections and corrective actions.

Who should pay attention

  • companies that distribute or import BMC/Luna ventilators
  • sleep clinics and home-care providers using APAP/BPAP devices
  • quality teams handling complaints and MDR reporting for software-connected devices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk